Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

SIMPLE SUMMARY: Hepatocellular carcinoma is an aggressive cancer with high mortality. The introduction of immune-checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) has led to a paradigmatic change in the systemic treatment of HCC. However, the important challenges o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yawen, Wong, Jeffrey Sum Lung, Sugimura, Ryohichi, Lam, Ka-On, Li, Bryan, Kwok, Gerry Gin Wai, Leung, Roland, Chiu, Joanne Wing Yan, Cheung, Tan To, Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072916/
https://www.ncbi.nlm.nih.gov/pubmed/33919570
http://dx.doi.org/10.3390/cancers13081949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072916/
https://www.ncbi.nlm.nih.gov/pubmed/33919570
http://dx.doi.org/10.3390/cancers13081949

Ejemplares similares